Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reininger

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Hamostaseologie|December 18, 2013
Recruitment update of AHEADJ Oldenburg, R Zimmermann, A Huth-Kühne, et al.
Clinical Transplantation|April 26, 2021
A retrospective analysis of the safety and efficacy of apixaban use after lung transplantKevin A Reininger, Teena Sam, Raksha S Patel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 28, 2017
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statementA Iorio, E Iserman, V Blanchette, et al.
Clinical Transplantation|December 26, 2022
Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizersKevin A Reininger, Guillaume Onyeaghala, Teresa Anderson-Haag, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Hamostaseologie|December 18, 2013
Recruitment update of AHEADJ Oldenburg, R Zimmermann, A Huth-Kühne, et al.
Clinical Transplantation|April 26, 2021
A retrospective analysis of the safety and efficacy of apixaban use after lung transplantKevin A Reininger, Teena Sam, Raksha S Patel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 28, 2017
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statementA Iorio, E Iserman, V Blanchette, et al.
Clinical Transplantation|December 26, 2022
Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizersKevin A Reininger, Guillaume Onyeaghala, Teresa Anderson-Haag, et al.
Pageof 2